Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –
Unleashing tools to accelerate breakthroughs in human health™ –
today announced a collaboration agreement with Navignostics AG for
development of clinical research applications and service offerings
using the Hyperion XTi™ Imaging System.
This collaboration is pivotal in the fight against cancer,
emphasizing the need for precision medicine strategies and robust
technologies that offer critical biological insights to guide
treatment decisions. Imaging Mass Cytometry™ is purpose-built to
clearly generate and differentiate these insights to help inform
clinical outcomes, providing the opportunity to expand access to
high-quality data in clinical research.
Founded in 2022, Navignostics is dedicated to revolutionizing
personalized diagnostics for cancer patients. Its goal is to
identify the most effective treatment for each patient by using
innovative tumor analysis methods.
“We are very excited about this collaboration. Characterizing
tumors using spatial single-cell proteomics enables identification
of optimal treatments for an individual patient’s tumor and helps
accelerate drug development by providing key insights into drug
mechanisms and tumor features. Our ability to automate and
standardize this process with IMC™ has really pushed us to where we
are now, bringing novel developments into the clinical space to
help inform treatment decisions for cancer patients,” said Jana
Fischer, Chief Executive Officer of Navignostics.
The Hyperion™ XTi Imaging System is a significant advancement in
clinical research, offering rapid, robust data acquisition and
extended system stability essential for product and drug
development. The machine learning process used by Navignostics to
discover predictive patterns, and ultimately patient care, demand
high throughput, dependable precision and the ability to scale that
the Hyperion XTi™ can provide. In clinical studies, Navignostics
demonstrated its ability to go from samples to data reporting in
under 72 hours, with efforts to further reduce this time.
As part of the agreement, Standard BioTools will support the
development of Navignostics assays by collaborating on various
aspects of protocols and instrument and software features.
Additionally, both Navignostics and Standard BioTools plan to
leverage their learnings to advance the science of IMC by
co-publishing and presenting at scientific conferences in the
coming year.
“In line with the Standard BioTools™ mission to accelerate
breakthroughs in human health, our exciting partnership with
Navignostics helps bring Imaging Mass Cytometry to the forefront of
clinical research by generating the quality of data that can be
translated into tangible results,” said Michael Egholm, President
and CEO of Standard BioTools. “We are proud that the use of IMC and
the advanced features of Hyperion XTi are core to their goal of
developing methods and insights that will help cancer patients
reach better outcomes, and we continue to enhance the system to
further support their progress.”
Among key growth strategies for Standard BioTools is enabling
new spatial biology applications in translational and clinical
research by accelerating the development of turnkey panels, leading
with new antibody targets through increased organic investment and
partnership.
Use of Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements regarding the potential
benefits of research conducted using Standard BioTools products and
technologies and the expected performance of such products and
technologies. Forward-looking statements are subject to numerous
risks and uncertainties that could cause actual results to differ
materially from what is currently anticipated, including but not
limited to risks relating to interruptions or delays in the supply
of components or materials for, or manufacturing of, Standard
BioTools products; potential product performance and quality
issues; intellectual property risks; competition; uncertainties in
contractual relationships; and reductions in research and
development spending or changes in budget priorities by customers.
Information on these and additional risks and uncertainties and
other information affecting Standard BioTools business and
operating results is contained in its Annual Report on Form 10-K
for the year ended December 31, 2022, and in its other filings with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Standard BioTools
disclaims any obligation to update these forward-looking statements
except as may be required by law.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as
Fluidigm Corporation, is driven by a bold purpose – Unleashing
tools to accelerate breakthroughs in human health. Standard
BioTools has an established portfolio of essential, standardized
next-generation technologies that help biomedical researchers
develop medicines faster and better. As a leading solutions
provider, the company provides reliable and repeatable insights in
health and disease using its proprietary mass cytometry and
microfluidics technologies, which help transform scientific
discoveries into better patient outcomes. Standard BioTools works
with leading academic, government, pharmaceutical, biotechnology,
plant and animal research and clinical laboratories worldwide,
focusing on the most pressing needs in translational and clinical
research, including oncology, immunology and immunotherapy. Learn
more at standardbio.com or connect with us on X, Facebook®,
LinkedIn and YouTube™. Standard BioTools, the Standard BioTools
logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate
breakthroughs in human health,” Imaging Mass Cytometry, IMC,
Hyperion, Hyperion XTi and XTi are trademarks and/or registered
trademarks of Standard BioTools Inc. or its affiliates in the
United States and/or other countries. All other trademarks are the
sole property of their respective owners. Standard
BioTools products are provided for Research Use Only. Not for use
in diagnostic procedures.
About Navignostics AG
Navignostics is a spin-off company from the University of
Zurich, founded in April 2022, which is leveraging spatial
single-cell proteomics to perform advanced analyses of tumor
samples. As a start-up active in the personalized medicine field,
Navignostics strives to provide innovative solutions to identify
the best possible treatment for each cancer patient. In addition,
Navignostics provides advanced services to pharmaceutical companies
to accelerate cancer drug development and to contribute to
companion diagnostic development.
Available Information
Standard BioTools uses its website (standardbio.com), investor
site (investors.standardbio.com), corporate X account
(@Standard_BioT), Facebook page (facebook.com/StandardBioT), and
LinkedIn page (linkedin.com/company/standard-biotools) as channels
of distribution of information about its products, its planned
financial and other announcements, its attendance at upcoming
investor and industry conferences and other matters. Such
information may be deemed material information, and Standard
BioTools may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor Standard BioTools website and its social media accounts in
addition to following its press releases, SEC filings, public
conference calls and webcasts.
Standard BioTools Contacts:Investors
Peter DeNardoCapComm Partnersir@standardbio.com
Media
Nick Lamplough / Dan Moore / Tali
EpsteinCollected StrategiesLAB-CS@collectedstrategies.com
Navignostics Contact:
info@navignostics.ch www.navignostics.com
Standard BioTools (NASDAQ:LAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Standard BioTools (NASDAQ:LAB)
Historical Stock Chart
From Apr 2023 to Apr 2024